Investor Presentaiton

Targeted Protein Degradation platform is poised for a step-change in productivity Growing asset library • Extensive number of potential INDs identified Opportunities across therapeutic areas Industry-leading capabilities Significant experience applying preclinical, manufacturing, translational, Al/digital and clinical tools to optimize candidates Ill Bristol Myers Squibb™ Engine expected to deliver approximately 4 INDs annually Not for Product Promotional Use 142

View entire presentation